Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$6.41 - $9.95 $272,008 - $422,228
42,435 New
42,435 $388,000
Q1 2022

May 13, 2022

SELL
$5.46 - $8.29 $128,310 - $194,814
-23,500 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$7.34 - $11.18 $172,490 - $262,730
23,500 New
23,500 $190,000
Q3 2018

Nov 09, 2018

SELL
$4.08 - $7.14 $44,223 - $77,390
-10,839 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$5.89 - $7.78 $203,599 - $268,931
-34,567 Reduced 76.13%
10,839 $66,000
Q1 2018

May 03, 2018

BUY
$6.76 - $11.7 $209,762 - $363,051
31,030 Added 215.85%
45,406 $331,000
Q4 2017

Feb 09, 2018

SELL
$8.03 - $11.25 $175,391 - $245,722
-21,842 Reduced 60.31%
14,376 $118,000
Q3 2017

Nov 09, 2017

BUY
$8.35 - $10.5 $302,420 - $380,289
36,218
36,218 $380,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.